Certified Nurse-Midwife Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mina Hignutt

Advanced Practice Midwife Chandler, AZ Certified Nurse-Midwife

NPI 1508182817 CMS profile 10800404

655 S Dobson Rd Ste 101, Chandler, AZ 85224

Open in the dashboard

General payments

$3,603

194 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mina Hignutt of Chandler, AZ is reported in the CMS Open Payments database as having received $3,603 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Advanced Practice Midwife profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $617 29
2024 General $666 31
2023 General $856 44
2022 General $729 43
2021 General $735 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mina Hignutt
  • Advanced Practice Midwife median
  • Middle half of Advanced Practice Midwife
  • National median

In program year 2025, general payments to Mina Hignutt were reported at $617. Among 4,127 Advanced Practice Midwife profiles paid that year, the median was $71 and the middle half received between $28 and $161.

Show as a table
Year Mina Hignutt Advanced Practice Midwife median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $735 $57 $22–$142 $132
2022 $729 $61 $23–$157 $149
2023 $856 $68 $26–$167 $160
2024 $666 $63 $25–$142 $164
2025 $617 $71 $28–$161 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $771 50 payments
  2. Mayne Pharma Inc. $321 15 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $286 12 payments
  4. Organon LLC $223 12 payments
  5. Sumitomo Pharma America, Inc. $218 14 payments
  6. Evofem Biosciences, Inc. $179 11 payments
  7. Astellas Pharma US Inc $169 7 payments
  8. Exeltis, USA Inc. $158 11 payments
  9. Myovant Sciences Inc. $151 9 payments
  10. CooperSurgical, Inc. $146 5 payments
  11. Other $981 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,603 194 payments
Products named General payments · program years 2021–2025
  1. MYFEMBREE $346 22 payments
  2. LILETTA $326 15 payments
  3. LO LOESTRIN FE $303 24 payments
  4. Mirena $229 9 payments
  5. Kyleena $211 8 payments
  6. NEXPLANON $185 10 payments
  7. Phexxi $179 11 payments
  8. Veozah $169 7 payments
  9. PARAGARD T 380A $132 4 payments
  10. ORILISSA $128 9 payments
  11. Other $1,560 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$1,638

Medicare's payments for the services billed

Medicare patients

13

Average age 72

Services billed

24

13 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $37
$37 — —
ABRYSVO
  • PFIZER INC. $33
$33 — —
SLYND
  • Exeltis, USA Inc. $27
$27 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $21
$21 — —
NUVARING
  • Organon LLC $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record